The first drug with a specific indication for eosinophilic esophagitis appears to be nearing approval in the United States.
A multicenter, placebo-controlled trial found that an oral suspension of budesonide from the drugmaker Takeda was well tolerated and met all of its efficacy end points, according to Ikuo Hirano, MD, a professor of medicine at Northwestern University Feinberg School of Medicine, in Chicago, who helped conduct the study.
The phase 3 trial enrolled 322 people with eosinophilic